Figure 6. Effects of p38 mitogen-activated protein kinases (MAPK) inhibitor and nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) siRNA on retinal ganglion cells (RGCs) survival in retinal ischemia/reperfusion (I/R) injury. Control: normal retinas (A), the other five groups were individually as I/R (B), I/R+vehicle (0.1% DMSO; (C), I/R+control of siRNA in vehicle (Lipofectamine 2000 [Invitrogen] and DMEM/F12: no serum and no antibiotics; D) I/R+SB203580 (E) and I/R+NF-κB siRNA (F). The number of cells in the RGCL significantly was decreased in the central and peripheral retina by SB203580 and NF-κB siRNA when compared to the normal and I/R control (G). *Statistically significant compared to the I/R group: p<0.05. ** Statistically significant compared to the normal control: p<0.05. Data were given as mean±standard deviation (SD).